Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Satlin
Weill Medical College of Cornell University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Fransisco Medical Center
San Francisco, California, United States
- Hackensack Meridian Health
Nutley, New Jersey, United States
- Mount Sinai Hospital
New York, New York, United States
- University of North Carolina Chapel Hill
Chapel Hill, North Carolina, United States
- Oregon Health and Science University
Portland, Oregon, United States
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Mar 2021
- Primary completion
- 30 Dec 2021
- Completion
- 28 Feb 2022
- Last update posted
- 6 Apr 2022
- Registered enrollment
- 168
- Registry id
- NCT04710212
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.